Header Logo

Connection

Robin Jones to Breast Neoplasms

This is a "connection" page, showing publications Robin Jones has written about Breast Neoplasms.
Connection Strength

1.766
  1. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011 Feb; 64(2):130-5.
    View in: PubMed
    Score: 0.263
  2. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23.
    View in: PubMed
    Score: 0.233
  3. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009 Jul; 116(1):53-68.
    View in: PubMed
    Score: 0.222
  4. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74.
    View in: PubMed
    Score: 0.197
  5. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7.
    View in: PubMed
    Score: 0.170
  6. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
    View in: PubMed
    Score: 0.082
  7. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011 Jan; 47(1):138-50.
    View in: PubMed
    Score: 0.065
  8. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
    View in: PubMed
    Score: 0.064
  9. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010 Oct; 23(10):1334-45.
    View in: PubMed
    Score: 0.064
  10. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3494-502.
    View in: PubMed
    Score: 0.055
  11. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 Sep; 111(1):27-44.
    View in: PubMed
    Score: 0.053
  12. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008 Jul; 110(2):245-56.
    View in: PubMed
    Score: 0.053
  13. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9.
    View in: PubMed
    Score: 0.050
  14. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007 Jan 01; 13(1):90-101.
    View in: PubMed
    Score: 0.050
  15. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23.
    View in: PubMed
    Score: 0.050
  16. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006 Jul; 19(7):999-1009.
    View in: PubMed
    Score: 0.048
  17. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006 Feb; 19(2):307-19.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.